FR3014695A1 - - Google Patents

Download PDF

Info

Publication number
FR3014695A1
FR3014695A1 FR1362814A FR1362814A FR3014695A1 FR 3014695 A1 FR3014695 A1 FR 3014695A1 FR 1362814 A FR1362814 A FR 1362814A FR 1362814 A FR1362814 A FR 1362814A FR 3014695 A1 FR3014695 A1 FR 3014695A1
Authority
FR
France
Prior art keywords
human
pcsk9
seq
ligand
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR1362814A
Other languages
English (en)
French (fr)
Inventor
Jasper Clube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to FR1362814A priority Critical patent/FR3014695A1/fr
Priority to EP14172578.8A priority patent/EP2886557A1/en
Priority to EP14172579.6A priority patent/EP2886558A1/en
Publication of FR3014695A1 publication Critical patent/FR3014695A1/fr
Priority to FR1652328A priority patent/FR3033703A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR1362814A 2013-12-17 2013-12-17 Withdrawn FR3014695A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1362814A FR3014695A1 (ja) 2013-12-17 2013-12-17
EP14172578.8A EP2886557A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172579.6A EP2886558A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
FR1652328A FR3033703A1 (ja) 2013-12-17 2016-03-18

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1362814A FR3014695A1 (ja) 2013-12-17 2013-12-17

Publications (1)

Publication Number Publication Date
FR3014695A1 true FR3014695A1 (ja) 2015-06-19

Family

ID=51292991

Family Applications (2)

Application Number Title Priority Date Filing Date
FR1362814A Withdrawn FR3014695A1 (ja) 2013-12-17 2013-12-17
FR1652328A Withdrawn FR3033703A1 (ja) 2013-12-17 2016-03-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR1652328A Withdrawn FR3033703A1 (ja) 2013-12-17 2016-03-18

Country Status (1)

Country Link
FR (2) FR3014695A1 (ja)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008011431A2 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2011072263A1 (en) * 2009-12-11 2011-06-16 Irm Llc Pcsk9 antagonists
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008011431A2 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2011072263A1 (en) * 2009-12-11 2011-06-16 Irm Llc Pcsk9 antagonists
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVIGNON J ET AL: "The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis", CURRENT ATHEROSCLEROSIS REPORTS, CURRENT SCIENCE, US, vol. 12, no. 5, 1 September 2010 (2010-09-01), pages 308 - 315, XP009163743, ISSN: 1523-3804, DOI: 10.1007/S11883-010-0123-6 *
HOPKINS PAUL N ET AL: "A Randomized Placebo-phase Clinical Trial With the Monoclonal Antibody Alirocumab Demonstrates Reductions in Low-density Lipoprotein Cholesterol in Patients With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function Mutations", CIRCULATION, vol. 128, no. 22, Suppl. S, November 2013 (2013-11-01), & SCIENTIFIC SESSIONS AND RESUSCITATION SCIENCE SYMPOSIUM OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 16 -17, 2013, pages 17156, XP002730991 *
JANICE MAYNE ET AL: "Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations", LIPIDS IN HEALTH AND DISEASE, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 10 May 2013 (2013-05-10), pages 70, XP021151113, ISSN: 1476-511X, DOI: 10.1186/1476-511X-12-70 *
KOTOWSKI I K ET AL: "A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 78, no. 3, 1 March 2006 (2006-03-01), pages 410 - 422, XP008100000, ISSN: 0002-9297 *
LI SHEN ET AL: "The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors", PHARMACOLOGICAL RESEARCH., vol. 73, 1 July 2013 (2013-07-01), GB, pages 27 - 34, XP055139387, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2013.04.001 *

Also Published As

Publication number Publication date
FR3033703A1 (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
US11434305B2 (en) Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
WO2015092394A1 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP2018203772A (ja) 被験者の特定のグループを処置する方法において使用するためのｐｃｓｋ９に対するヒト抗体
DE112014005747T5 (de) Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen
JP2019514907A (ja) 家族性高コレステロール血症を有する患者を処置するための方法
US9034331B1 (en) Targeting rare human PCSK9 variants for cholesterol treatment
SA515360248B1 (ar) أجسام مضادة cd26 واستخداماتها
JP2022078306A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
US9045548B1 (en) Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) Targeting rare human PCSK9 variants for cholesterol treatment
EP2886557A1 (en) Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
FR3014695A1 (ja)
EP2975059A1 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP2975058A1 (en) Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
DE202015008974U1 (de) Targeting von humaner PCSK9 zur Cholesterinbehandlung
TW201525005A (zh) 用於膽固醇治療之標靶人類第９型前蛋白轉換酶枯草桿菌蛋白酶（ｐｃｓｋ９）之技術
IES20140279A2 (en) Human targets II
DE202015009002U1 (de) Targeting von humaner PCSK9 zur Cholesterinbehandlung
DE202014010499U1 (de) Targeting von humaner PCSK9 zur Cholesterinbehandlung
IES86600B2 (en) An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level
GB2521356A (en) Human targets II
IES20140321A2 (en) An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20190906